We postulate that in this study, a single intravenous injection of adropin after ischemia may modulate cardiac microenvironment at the early stage of MI by suppressing inflammatory reaction, and adropin-pretreated MSCs may have stronger survival potential in the injured ischemic tissue, thus conferring the effects observed at day 28. The gene discussed is ENHO; the disease is myocardial infarction.